MPPE1 and Patent ductus arteriosus: Thus, while tumor-derived factors can interfere with cDC1 development in PDA (10–14), antigenicity and/or immunotherapy, both of which promote tumor-specific T cells (36, 37), override tumor-dependent cDC1 repression.